| Jennifer Christine Fendler, NP | |
|
924 N Country Club Dr, Mesa, AZ 85201-4108 | |
| (480) 601-3528 | |
| Not Available |
| Full Name | Jennifer Christine Fendler |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 924 N Country Club Dr, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003481847 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QA0505X | Family Medicine - Adult Medicine | 257625 (Arizona) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 257625 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Christine Fendler, NP 22702 N 39th Ter, Phoenix, AZ 85050-5408 Ph: (602) 799-3728 | Jennifer Christine Fendler, NP 924 N Country Club Dr, Mesa, AZ 85201-4108 Ph: (480) 601-3528 |
News Archive
Blocked arteries are typically the trigger, stopping the flow of blood and starving the heart muscle of oxygen. But when the blockage is removed and the blood comes rushing back, it wreaks havoc of its own. The result is called reperfusion injury, a life-threatening flood of inflammation and cellular destruction that has stumped scientists for 40 years.
NYU Langone Medical Center announced the establishment of its new Joan H. Tisch Center for Women's Health on the Upper East Side of Manhattan in New York City.
Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.
Baylor College of Medicine and the University of Houston are teaming up for new research collaborations.
Halozyme Therapeutics, Inc. announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze technology.
› Verified 7 days ago